On Thursday, Roth Capital reaffirmed their buy rating on shares of ImmunoCellular Therapeutics (NASDAQ:IMUC) in a report published on Thursday, MarketBeat Ratings reports. Roth Capital currently has a $3.00 price target
I's no longer a matter of IF, it's just a matter of WHEN....There are So may doctors and
nurses are talking about it with GREAT excitement ..... it's happening , so don't let the demons scare you, they just want to bring you down !. GO IMUC !!!!!!! This company WILL PREVAIL against all adversity !!!!